Mitsubishi UFJ Asset Management
RCKT icon

Mitsubishi UFJ Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,532
Closed -$113K – 1648
2025
Q3 		$113K Sell
34,532
-1,653
-5% -$5.21K ﹤0.01% 1026
2025
Q2 		$88.7K Buy
36,185
+14,300
+65% +$72.4K ﹤0.01% 1031
2025
Q1 		$146K Buy
21,885
+1,689
+8% +$16.7K ﹤0.01% 991
2024
Q4 		$254K Buy
20,196
+8,190
+68% +$123K ﹤0.01% 957
2024
Q3 		$222K Sell
12,006
-1,112
-8% -$22.8K ﹤0.01% 954
2024
Q2 		$282K Buy
13,118
+2,217
+20% +$50.9K ﹤0.01% 924
2024
Q1 		$294K Sell
10,901
-489
-4% -$13.9K ﹤0.01% 921
2023
Q4 		$327K Sell
11,390
-2,087
-15% -$46.1K ﹤0.01% 965
2023
Q3 		$276K Buy
13,477
+981
+8% +$17.8K ﹤0.01% 993
2023
Q2 		$248K Sell
12,496
-3,896
-24% -$78.7K ﹤0.01% 1015
2023
Q1 		$281K Buy
16,392
+973
+6% +$19.1K ﹤0.01% 985
2022
Q4 		$295K Sell
15,419
-9,786
-39% -$180K ﹤0.01% 979
2022
Q3 		$402K Buy
25,205
+444
+2% +$6.93K ﹤0.01% 923
2022
Q2 		$341K Buy
24,761
+13,200
+114% +$157K ﹤0.01% 982
2022
Q1 		$183K Buy
11,561
+932
+9% +$16.1K ﹤0.01% 1070
2021
Q4 		$252K Buy
10,629
+3,043
+40% +$83K ﹤0.01% 1043
2021
Q3 		$227K Buy
7,586
+211
+3% +$7.68K ﹤0.01% 1042
2021
Q2 		$327K Sell
7,375
-3,287
-31% -$143K ﹤0.01% 1027
2021
Q1 		$473K Buy
10,662
+3,525
+49% +$194K ﹤0.01% 900
2020
Q4 		$391K Sell
7,137
-2,998
-30% -$109K ﹤0.01% 860
2020
Q3 		$232K Buy
10,135
+115
+1% +$2.83K ﹤0.01% 880
2020
Q2 		$210K Sell
10,020
-1,542
-13% -$27.8K ﹤0.01% 887
2020
Q1 		$161K Buy
11,562
+2,397
+26% +$47.5K ﹤0.01% 874
2019
Q4 		$204K Buy
9,165
+713
+8% +$11.9K ﹤0.01% 868
2019
Q3 		$98K Buy
8,452
+1,585
+23% +$19.7K ﹤0.01% 908
2019
Q2 		$103K Sell
6,867
-4,146
-38% -$72.4K ﹤0.01% 913
2019
Q1 		$193K Buy
11,013
+814
+8% +$12.9K ﹤0.01% 808
2018
Q4 		$153K Buy
10,199
+3,598
+55% +$59.7K ﹤0.01% 784
2018
Q3 		$163K Buy
+6,601
New +$143K ﹤0.01% 792

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Mitsubishi UFJ Asset Management's RCKT Position: Q4 2025 in Review

Mitsubishi UFJ Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 34,532 shares — an estimated $113K sold.

Mitsubishi UFJ Asset Management first reported a position in RCKT in Q3 2018 and held it in 29 quarters. The position peaked at $473K in Q1 2021. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

  • Mitsubishi UFJ Asset Management reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 34,532 Rocket Pharmaceuticals shares in Q4 2025, an estimated $113K.
  • Mitsubishi UFJ Asset Management first reported a position in Rocket Pharmaceuticals in Q3 2018 and held it in 29 quarters.
  • Mitsubishi UFJ Asset Management's Rocket Pharmaceuticals position peaked at $473K in Q1 2021.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2025, filed 3 Feb 2026.